Investigational drug · Phase 2
mivelsiran
Also called: ALN-APP
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cerebral Amyloid Angiopathy, Down Syndrome-Associated Alzheimer's Disease (DS-AD).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "mivelsiran"
First trial start
2024
May 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "mivelsiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cerebral Amyloid Angiopathy
- Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Approved drugs for the same conditions: Alzheimer's disease · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "mivelsiran" as an intervention, largest first.
- A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyPivotal-lookingActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06393712 · 210 participants · Start May 17, 2024 · Primary completion Aug 9, 2027
Drug: Placebo; ALN-APP · For: Cerebral Amyloid Angiopathy
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 57 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT05231785 · 60 participants (planned) · Start Feb 4, 2022 · Primary completion Jan 11, 2029
Drug: ALN-APP; Placebo · For: Early-Onset Alzheimer Disease
Sites: La Jolla, California; Indianapolis, Indiana; Montreal, Canada · 8 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07636811 · 58 participants (planned) · Start Aug 17, 2026 · Primary completion May 18, 2030
Drug: Mivelsiran; Placebo · For: Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Sites: Maitland, Florida; Naples, Florida; Fishers, Indiana · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- C16-siRNAs in Focus: Development of ALN-APP, a Promising RNAi-Based Therapeutic for Alzheimer's Disease.
Titze-de-Almeida R, Oliveira Gomes GM, Santos TCD, et al. · Pharmaceuticals (Basel) 2025
Also in development for Cerebral Amyloid Angiopathy
- AMDX-2011PPhase 22 trials
Amydis Inc. · Cerebral Amyloid Angiopathy, Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Alnylam Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.